IFN-β gene-modified MSCs have been demonstrated to possess consistent anticancer effects for multiple tumors, such as bronchioloalveolar carcinoma, ovarian carcinoma, breast cancer, pancreatic cancer, and prostate cancer [15, 22–28]. This evidence concerns the gene IFNB1 and Familial prostate cancer.